ReviewCancer immunology research2015
Microbiota modulation of myeloid cells in cancer therapy.
Review in Cancer immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science (New York, N.Y.) · 2021Trial
- Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial.Respiratory research · 2020Trial
- Microbiome interactions in renal cell carcinoma: evidence, challenges and opportunities.Nature reviews. Urology · 2026Review
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention.Nature reviews. Clinical oncology · 2025Review
- Correlation between gut microbiota and tumor immune microenvironment: A bibliometric and visualized study.World journal of clinical oncology · 2025Article
- Elucidation of the mechanism Underlying the promotion of ferroptosis and enhanced antitumor immunity by citrus polymethoxyflavones in CRC cells.Frontiers in pharmacology · 2025Article
- The Microbiome-TIME Axis: A Host of Possibilities.Microorganisms · 2023Review
- Effects of chemotherapy and immunotherapy on microbial diversity in TME and engineered bacterial-mediated tumor therapy.Frontiers in immunology · 2023Review
- Common themes in antimicrobial and anticancer drug resistance.Frontiers in microbiology · 2022Review
- Drug-Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics.Biomedicines · 2021Review
- Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy.Frontiers in immunology · 2021Review
- Review
- Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.Frontiers in immunology · 2020Review
- The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives.Clinical and experimental gastroenterology · 2020Review
- Toll-Like Receptor 9 Agonists in Cancer.OncoTargets and therapy · 2020Review
- Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?International journal of molecular sciences · 2019Review
- Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon.PloS one · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Myeloid cells represent a major component of the tumor microenvironment, where they play divergent dual roles. They can induce antitumor immune responses, but mostly they promote immune evasion, tumor progression, and metastasis formation. Thus, strategies aiming at reprogramming the tumor microenvironment represent a promising immunotherapy approach. Myeloid cells respond to environmental factors including signals derived from commensal microbes. In this Cancer Immunology at the Crossroads overview, we discuss recent advances on the effects of the commensal microbiota on myeloid-cell functions and how they affect the response to cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.